Advancing precision oncology through innovative bioconjugation and linker architecture strategies

The purpose of this study is to showcase how Vector Laboratories' proprietary bioconjugation technologies enable the development of highly specific and stable biomolecule conjugates, driving improvements in cancer detection and targeted therapy. We utilized Vector's advanced conjugation chemistries-including site-specific labeling and click chemistry-combined with optimized linker systems to create antibody-drug conjugates (ADCs) and diagnostic probes. Conjugates can be characterized using LC-MS, SEC, fluorescence imaging, and functional assays in tumor-derived cell lines to assess binding specificity, payload release, and signal amplification. Summary of New Data: The successful development of new antibody drug conjugates (ADCs) requires expert knowledge of antibody engineering, chemical biology, and linker architecture. BioDesign by Absolute Antibody and Vector Laboratories, provides drug developers ease of access to trusted antibody engineering, crucial bioconjugation products, and unique linker IP. These critical elements in the BioDesign toolbox help to maximize life science development versatility, overcome resource constraints, manufacturing at scale, and decrease time-to-market. Vector will showcase data highlighting how dPEG-based linkers have enhanced the therapeutic profile of ADCs, supported by recent bioassay results. In summary, Vector Laboratories' bioconjugation capabilities deliver precise, reproducible, and scalable solutions for oncology research and clinical applications. These findings underscore the potential of our platform to enhance therapeutic efficacy and diagnostic accuracy in cancer care.